ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require upwards or assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Jason Letman, Chief Executive Officer. Thank you. You may begin. Thank you, and welcome to our Q4 and fiscal year 2025 results call. Appreciate you all spending some time with us this morning. As usual, we will be making forward-looking statements during the call, so please refer to our FOS slide in our corporate deck. With me today, we have Harish Antharam, our CFO, as well as our CMO, Dr. Barb Klinke. And in terms of the first bit of news, we're delighted to announce today that Barb will continue leading our clinical efforts as our permanent chief medical officer. Welcome, Barb. As many of you know, after joining in an interim capacity in September 2025, Barb has been absolutely instrumental in driving our development programs forward over the last five months. Barb, as many of you also know, is an incredibly experienced oncologist and drug developer. having served as CMO at Sierra Oncology and having senior roles at both Onyx and Genentech before that. We're beyond fortunate to add Barb during this critical inflection for the company and thrilled to welcome her permanently. And I'll turn the call over to her later today to walk through some of our clinical updates. In terms of the agenda and the goals for today, we will review our key Q4 2025 and year-to-date accomplishments. referencing our press release and corporate deck available on ...